Oculis Holding AG

OCS Healthcare Biotechnology

Oculis Holding AG’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million, up 85.7% from fiscal 2024. In the quarter to June 2026, revenue grew 24.0%, EPS grew 66.1%, free cash flow fell 10.4% and total debt rose 159.8%, each against the same quarter a year earlier.

7.29 0.11 −1.49%
Market cap
$456.8M
P/E
0.0×
Fwd P/E
−5.1×
Dividend yield
—
F-score
4/9
Altman Z
10.51
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
977.18 720.95 1,121.34 577.09
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(50.81) (57.88) (80.03) (33.41)
P/B ratio
5.64 4.41 6.24 3.06
EV/Sales
787.71 545.04 920.42 382.70
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(9.66) (9.65) (16.04) (6.82)
Current Ratio
4.47 5.96 5.18 8.35
Net Debt/EBITDA
7.11 9.94 10.21 9.68
Debt/Equity
0.02 0.01 0.01 0.01
Earnings Yield
(14.33%) (11.37%) (8.01%) (12.55%)
Free Cash Flow Yield
(8.35%) (7.83%) (5.12%) (9.73%)
Free Cash Flow per Share
(0.35) (0.34) (0.33) (0.42)
Book value per Share
3.12 4.53 4.26 4.53
Free Cash Flow
(18.32) (18.01) (19.58) (25.45)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates